Quantum Biopharma (QNTM) Cash & Equivalents (2018 - 2026)

Quantum Biopharma's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 68.22% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 68.22% YoY), while the FY2025 annual figure was $1.9 million, down 68.22% from the prior year.
• Cash & Equivalents came in at $1.9 million for Q1 2026 at Quantum Biopharma, roughly flat from $1.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $31.6 million in Q2 2022 to a low of $1.9 million in Q4 2025.
• A 5-year average of $10.2 million and a median of $6.0 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 84.7% in 2023 and jumped 117.47% in 2025, its largest moves.
• Quantum Biopharma's Cash & Equivalents stood at $17.0 million in 2022, then plunged by 78.6% to $3.6 million in 2023, then jumped by 65.0% to $6.0 million in 2024, then sank by 68.22% to $1.9 million in 2025, then changed by 0.0% to $1.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.9 million, $1.9 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison